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Abstract Prion diseases in humans are neurodegenerative
diseases which are caused by an accumulation of abnormal,
misfolded cellular prion protein known as scrapie prion pro-
tein (PrPSc). Genetic, acquired, or spontaneous (sporadic)
forms are known. Pathogenic mutations in the human prion
protein gene (PRNP) have been identified in 10–15 % of CJD
patients. These mutations may be single point mutations,
STOP codon mutations, or insertions or deletions of octa-
peptide repeats. Some non-coding mutations and new muta-
tions in the PrP gene have been identified without clear evi-
dence for their pathogenic significance. In the present review,
we provide an updated overview of PRNP mutations, which
have been documented in the literature until now, describe the
change in the DNA, the family history, the pathogenicity, and
the number of described cases, which has not been published
in this complexity before. We also provide a description of
each genetic prion disease type, present characteristic histo-
pathological features, and the PrPSc isoform expression pat-
tern of various familial/genetic prion diseases.
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Introduction
Transmissible spongiform encephalopathies (TSE) or prion
diseases are fatal neurodegenerative disorders, which are char-
acterized by the aggregation and accumulation of misfolded
scrapie prion protein (PrPSc) in brain tissue. TSE can occur
spontaneously (sporadic), hereditary or acquired, most as iat-
rogenic cases. Hereditary prion diseases are categorized by
certain clinical and pathological features as familial CJD
(fCJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), or
fatal familial insomnia (FFI). Since more than 50 % of those
cases have been reported without a family history, the term
Bgenetic CJD (gCJD)^ is now being used more frequently
than BfCJD^ [1]. Genetic CJD describes a single CJD case,
where a mutation in the PrP gene seems to make the conver-
sion into the abnormal form more likely. In some cases, it is
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In contrast, in hereditary CJD or fCJD cases, the person has
a family history of the disease and a positive test for a genetic
mutation associated with CJD.
Since the sensitivity of most diagnostic tests (e.g., 14-3-3,
RT-QuIC orMRI) is lower in some hereditary diseases such as
FFI [2, 3] than in sporadic CJD (sCJD), a detailed clinical
examination and clinical history is extremely important. A
confirmed diagnosis of a hereditary prion disease requires
the detection of a pathogenic PRNP mutation, a progressive
neuropsychiatric disorder, and post mortem confirmation at
autopsy [4].
The clinical onset of gCJD/fCJD usually occurs at an ear-
lier age (between 30 and 70 years) compared to sCJD [5] and
begins with memory impairment, confusion, myoclonus, and
ataxia.
Several PRNP mutations (such as V210I or E200K) are
associated with a variable disease onset and a heterogenic
penetrance [6]. The penetrance of the disease increased with
age, e.g., when mutation carriers survive to age over 80 years,
the penetrance is almost 100 % [7]. In contrast, at an age of
70 years, the penetrance is markedly decreased [7].
In sCJD patients, the methionine/valine (M/V) polymor-
phism at codon 129 of PRNP has a major influence on the
susceptibility to and the progression of the disease [8–10].
Similar to sCJD, the clinicopathological phenotype in
gCJD/fCJD may also depend on the M/V polymorphism
at codon 129 of the mutated allele, e.g., in E200K carriers
[11]. In octa-peptide repeat insertion (OPRI) mutation car-
riers, PRNP codon 129 M/M carriers exhibit an earlier
disease onset compared to M/V carriers [5, 12]. However,
in most of the genetic cases the influence of the PRNP
codon 129 polymorphism on the clinicopathological pheno-
type has not yet been described well because of the rare-
ness of the cases.
In certain PRNP mutations, e.g., D178N, the codon 129
polymorphism may even determine two completely distinct
phenotypes. Traditionally, the 178 mutation in association
with methionine at codon 129 has been termed FFI, while a
coupling with valine at codon 129 causes different pathology,
so that the disease was called fCJD [13]. In addition to the
gene polymorphism in PRNP, more than 50 mutations in the
open reading frame of PRNP have been described.
In the present review, we provide an updated overview of
the reported mutations, describe major differences in the PrPSc
expression profile, and present characteristic histopathological
features of selected genetic prion diseases.
Types of PRNPMutationsMayCause Different Kind
of Prion Diseases
The 253 amino acid PrP is encoded by the second exon of
PRNP [14]. All hereditary prion diseases are caused by a wide
variety of mutations in the prion protein gene (PRNP), which
is located on the short (p) arm of chromosome 20 (20p12),
[15, 16]. All of these mutations are autosomal dominant.
Among these mutations, point mutations in certain codons,
multiple-point mutations, premature STOP codon mutations,
or insertion/deletion of octa-peptide repeats in the N-terminal
domain of PRNP have been reported [9, 17–19]. However,
PRNP mutations also may appear spontaneously with an un-
known family history or with an unknown phenotype.
Hereditary CJD Caused by Point or Insert
Mutations
Genetic CJD can be caused by a variety of point mutations
which are summarized in Table 1 or by insertional mutations
in the octa-peptide region of PrP, summarized in Table 2
(Tables 1 and 2). The most common mutations in the
European population are mutations at codons 178, 200, and
210. Clinically and neuropathologically E200K and V210I
carriers resemble sCJD. The average age of onset is between
50 and 70 years of age, and the disease duration is often less
than 6 months. The family history of V210I is relatively low
(12 %) compared to E200K (49 %) [9].
In the E200K mutation carriers, immunohistochemical de-
tection of PrPSc aggregates usually show indistinguishable
pattern from sCJD (MM1) cases (Fig. 1a); some cases show
stripe-like deposits of PrPSc in the molecular layer of the cer-
ebellum (Fig. 1b, c) [127]. Biochemical typing revealed dif-
ferent types of PrPSc which can be distinguished by the mo-
lecular weight (type 1 of 21 kDa, type 2 of 19 kDa) of the
unglycosylated PrP isoform. V210I and E200K codon 129
MM carriers show a similar composition of the PrPSc isoform
pattern, consisting of di-, mono-, and unglycosylated PrP
(Fig. 4b). The PrP pattern is comparable to that of sCJD
(MM1) patients (Fig. 4b). PrPSc type 1 is typically associated
with fCJD E200K and V210I (PRNP codon 129 MM), while
PrPSc type 2 is associated with fCJD E200K codon 129 VV
(Fig. 4b).
Hereditary CJD Caused by STOP Codon Mutations
Some point mutations integrate a stop codon at different po-
sitions within PRNP resulting in the production of abnormal,
truncated forms of PrP. STOP codonmutations are very rare in
inherited prion diseases and they are accompanied by unusual
phenotypes. Examples of STOP mutations are Y145X (tangle
pathology), Q160X, Y163X, Y226X, or Q227X [18, 42, 46,
128]. Of these PRNP STOP mutations, Q160X and Q227X
cause an Alzheimer disease-like pathology with either amy-
loid plaques, neurofibrillary tangle lesions, or both [18, 128].
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39 ccg→ ctg n.d. n.d. n.d. Pro→Leu n.d. FTLD [20, 21]
52 n.d. n.d. n.d. No Gln→Pro MV Atypical CJD [22]
54 ggt→ agt No No Yes Gly→Ser MM n.d. [23]
84 n.d. n.d. Yes Yes Pro→Ser MV GSS [24]
97 agt→ aat n.d. n.d. n.d. Ser→Asn MM Probable AD [25]
102 ccg→ ctg n.d. Yes Yes Pro→Leu MM GSS [26, 27]
105 cca→ cta Yes Yes Yes Pro→Leu VV GSS [28]
105 cca→ aca n.d. n.d. No Pro→Thr VV GSS [29]
105 cca→ tca n.d. n.d. n.d. Pro→Ser VV GSS [30]
114 ggt→ gtt n.d. Yes Yes Gly→Val MM, MV gCJD [31]
117 gca→ gtg Yes Yes Yes Ala→Val VV GSS [32, 33]
127 ggc→ gtc n.d. n.d. n.d. Gly→Val MM Protective
against Kuru
[34–36]
131 gga→ gta n.d. Yes Yes Gly→Val MM, MV GSS [37, 38]
132 agt→ att n.d. n.d. n.d. Ser→ Ile MM GSS [39]
133 gca→ gtg No n.d. Yo Ala→Val MM GSS [40]
142 ggc→ agc n.d. n.d. Yes Gly→Ser MM, MV n.d. [23]
145 tat→ tag n.d. Yes n.d. Tyr→Stop MM GSS, AD [41, 42]
148 cgt→ cat Yes Yes Yes Arg→His MM fCJD [43]
160 caa→ taa Yes Yes Yes Gln→Stop MM, MV Dementia [44]
163 tat→ tag n.d. n.d. Yes Tyr→Stop VV GSS [45–47]
167 gat→ aat n.d. n.d. n.d. Asp→Asn n.d. n.d. [23]
167 gat→ ggt n.d. n.d. n.d. Asp→Gly MM n.d. [23]
171 aac→ agc n.d. n.d. No Asn→Ser MV, VV Unknown [48]
173 aac→ aag n.d. n.d. n.d. Asn→Lys MV n.d. [22]
176 gtg→ ggg n.d. Yes No Val→Gly VV Unusual GSS [49]
178-129 V gac→ aac Yes n.d. Yes Asp→Asn VV fCJD [50, 51]
178-129 M gac→ aac n.d. n.d. Yes Asp→Asn MM FFI [52]
180 gtc→ atc n.d. Yes Yes Val→ Ile MM gCJD [53, 54]
183 aca→ acg Yes Yes Yes Thr→Ala MM fCJD [55]
187 cac→ cgc Yes Yes Yes His→Arg VV Probable GSS [56, 57]
188 acg→ aag n.d. Yes Yes Thr→Lys n.d. gCJD [44, 58]
188 acg→ gcg n.d. Yes Yes Thr→Ala MM gCJD [59]
188 acg→ agg n.d. Yes Yes Thr→Arg VV Criteria for CJD
are not fulfilled
[19, 60]
193 acc→ att n.d. n.d. No Thr→ Ile MM Probable CJD [61]
196 gag→ aag Yes Yes Yes Glu→Lys MM, MV fCJD [62]
196 gag→ gcg n.d. Yes No Glu→Ala n.d. gCJD [63]
198 ttc→ gtc n.d. n.d. No Phe→Val VV, MM Probable AD [25]
198 ttc→ tcc Yes Yes Yes Phe→Ser MV GSS [64, 65]
200 gag→ aag n.d. n.d. Yes Glu→Lys MV fCJD [66]
200 gag→ ggg n.d. Yes No Glu→Gly MV fCJD [67]
202 gac→ aac n.d. Yes n.d. Asp→Asn VV GSS [68]
202 gac→ ggc n.d. n.d. No Asp→Gly VV Slow progressive dementia
syndrome
[69]
203 gtt→ att n.d. Yes Yes Val→ Ile MM gCJD [62, 70]
203 gtt→ ggt n.d. n.d. n.d. Val→Gly n.d. Probable fCJD [22]
208 cgc→ cac No Yes Yes Arg→His MM gCJD [71, 72]
208 cgc→ tgc n.d. n.d. No Arg→Cys MM Probable AD [25]
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Further characteristic phenotypes such a cerebral amyloid-
osis can be observed in Y145X and Y226X carriers [18, 42],
while Y163X is accompanied by chronic diarrhea with
dysautonomia [46], suggesting a variable phenotype of certain
PRNP mutation which is not always typical for a prion
disease.
Insertion Mutations
Human PRNP consists of a nona-peptide (PQGGGTWGQ)
followed by a tandem repeat of four copies of an octa-
peptide (PHGGGWGQ). These repeats are located between
amino acid residues 51 and 91. The normal structure of the
five repeats has been designated R1-R2-R2-R3-R4. R1 en-
codes a nona-peptide, while R2 to R4 encode octa-peptides
of the formula P(H/Q)GGG(−/G) WGQ.
By non-coding nucleotide differences, R2, R3, and R4 are
each distinguished from R1. Patients with an octa-peptide re-
peat insertion (OPRI) may have either one or up to 12 addi-
tional octa-repeats in PRNP (Table 2). The cause of this extra
repeat formation might be an unequal crossover and recombi-
nation [17].
The clinical picture of this group of patients (>30
cases) may range from that of classical CJD to that of a
GSS-type illness of long duration [129]. In most cases,
there is a correlation between the length of the inserts,
the age of onset and the duration of the disease. With
an increase in the insert numbers from one to seven, the
duration of the illness can range from 5 to 120 months
[15]. The majority of the patients have a chronic course
with aphasia, apraxia, cerebral ataxia, extrapyramidal fea-
tures, and memory loss [17, 116, 119]. However, patients
with one, two, or four extra repeats may have a phenotype
similar to sCJD [5]. The clinical pathological features of
patients with five, six, seven, eight, and nine extra repeats
are reminiscent of Gerstmann-Sträussler-Scheinker syn-
drome or atypical dementia [93, 130].
In octa-peptide repeat insertion patients, immunohisto-
chemical detection of PrPSc aggregates usually show a patchy
or tigroid pattern (Fig. 1d–h). Additionally, they may show
coarse and plaque-like PrPSc deposits (Fig. 1g, in case of 4
OPRI) or a tigroid pattern (Fig. 1h, 5 OPRI) in the cerebellar
cortex. The PrPSc aggregate pattern indicates a similar pattern
comparable to sCJD VV2 patients (Fig. 1i). Most of the OPRI
patients express the proteinase K-resistant PrPSc type 2
(Fig. 4b) according to the system described by Parchi et al.
[10]. In single cases, PrPSc type 1 may be expressed, as shown
for a 4-OPRI codon 129 MM (Fig. 4b).
FFI-Related Mutations
FFI, the most common genetic prion disease worldwide, typ-
ically begins with sleep and vigilance disturbances, cognitive
deficits, spatial disorientation, hallucinations, autonomic dis-
turbance, and motoric signs with an onset between 36 and
62 years (average: 56 years). FFI was reported initially as
thalamic dementia [131, 132]. The duration of the disease











209 gtg→ atg n.d. n.d. No Val→Met VV n.d. [23]
210 gtt→ att Yes Yes Yes Val→ Ile MM fCJD [73, 74]
211 gag→ cag Yes Possible Yes Glu→Gln MM fCJD [62, 75]
211 gag→ gac n.d. n.d. n.d. Glu→Asp VV gCJD [76]
212 cag→ ccg n.d. Yes n.d. Gln→Pro MM, VV GSS [23]
215 atc→ gtc Yes Yes Yes Ile→Val MM fCJD [77]
217 cag→ cgg Yes Yes Yes Gln→Arg VV GSS [78]
218 tac→ aac Yes Yes Yes Tyr→Asn VV GSS [79]
219 gag→ aag n.d. n.d. Yes Glu→Lys MM GSS [80, 81]
226 tac→ taa No Yes No Tyr→Stop VV GSS [18, 80, 81]
227 cag→ tag No Yes No Gln→Stop VV GSS [18]
232 atg→ agg Yes Yes Yes Met→Arg MM fCJD [82–84]
238 cca→ tca Yes Yes Yes Pro→Ser MM fCJD [19]
Details about the gene codon, change in DNA sequence, familial history, pathology, number of cases, change in amino acid sequence, type of disease,
and corresponding reference are indicated for each PRNP mutation. Lacking information is marked as not-described (n.d.)
Mol Neurobiol
6 and 72 months with an average duration of approximately
11 months in MM cases while MV cases exhibit an average
disease duration of 23 months [3, 52, 133–135]. However,
opposed to the first reported FFI patients, more recent studies
indicated that the clinical course of patients with a FFI muta-
tion resembled sCJD without any insomnia symptoms. These
observations challenge the widely accepted assumption that
codon 129 MM homozygosity is always related to a FFI phe-
notype [135, 136].
Typically, FFI patients exhibit severe neuronal loss in the
anterior ventral and mediodorsal thalamic nuclei and the infe-
rior olivary nucleus associated with prominent astrogliosis
and microglial activation (Fig. 2a, b). In the cerebellum, ex-
tensive Purkinje cell loss can be observed frequently
Table 2 Overview of octa-peptide repeat deletion/insertion (OPRI) mutations
Coding change Insert Sequence PRNP
codon 129
Disease >1 cases Reference
None No R1,R2,R2,R3,R4 All None n.d. [17]
24 bp deletion −1 R2 or R2,R3 or R2,R4 MM None n.d. [85]
24 bp insertion 1 R1,R2,R2,R2,R3,R4 n.d. n.d. n.d. [86]
48 bp insertion 2 2R1,R2,R2,R3,R2a,R2a,R4 MM fCJD-like Yes [87]
48 bp insertion 2 R1,R2, R2a,R2,R2a,R2a,R4 VV n.d. No [88]
48 bp insertion 2 R1,R2,R2a,R2,R2a,R2a,R4 MV Dementia n.d. [89]
72 bp insertion 3 R1,R2,R2,R3g,R2,R2,R3,R4 VV gCJD n.d. [90]
72 bp insertion 3 R1,R2,R2,R2a,R2,R2,R3,R4 MM Still healthy n.d. [91]
72 bp insertion 3 R1,R2,R2,R3g,R2,R2,R3,R4 MM Probable fCJD n.d. [92]
96 bp insertion 4 R1,R2,R2,R3g,R2,R3g,R2,R3,R4 MM gCJD n.d. [93]
96 bp insertion 4 R2,R3,R2,R3 MM n.d. n.d. [17]
96 bp insertion 4 R1,R2(6),R3,R4 MM gCJD n.d. [94]
96 bp insertion 4 R1,R2,R2,R3,R2,R2,R2,R3,R4 VV gCJD n.d. [86]
96 bp insertion 4 n.d. MM gCJD n.d. [12]
96 bp insertion 4 R1,R2,R2,R3,R2,R2,R2,R3,R4 MV gCJD n.d. [95]
96 bp insertion 4 R1, R2,R2,R2,R3,R2,R2, R3,R4 MM Dementia n.d. [96]
120 bp insertion 5 R1,R2(2),R3,R2,R3g,R2(2),R3,R4 n.d. fCJD Yes [17]
120 bp insertion 5 R1,R2(2),R3,R2,R2,R2,R2,R3,R4 MM fCJD Yes [97]
120 bp insertion 5 n.d. MM Atypical fCJD n.d. [98]
120 bp insertion 5 R1,R2,R2,R3g,R3g,R3g,R2,R2,R3,R4 MV fCJD Yes [99]
120 bp insertion 5 R1,R2,R3,R2,R3,R2,R3g,R2,R3,R4 MM n.d. n.d. [100]
144 bp insertion 6 R1,R2,R2,R2,R3,R2,R3g,R2,R2,R3,R4 MM n.d. Yes [101]
144 bp insertion 6 n.d. n.d. gCJD n.d. [102]
144 bp insertion 6 R1,R2(3),R3,R2,R3g,R2(2),R3,R4 n.d. n.d. n.d. [103]
144 bp insertion 6 R1,R2(2),R3g,R2(2),R3g,R2(2),R3,R4 MM fCJD Yes [104]
144 bp insertion 6 R1,R2,R2,R3,R2,R3g,R2,R3g,R2,R3,R4 n.d. fCJD Yes [105]
144 bp insertion 6 R1,R2,R2,R2(6),R3,R4 MV fCJD Yes [106]
144 bp insertion 6 R1,R2,R2,[R3,R2,R3g,R2,R2,R2],R3,R4 MV GSS n.d. [107]
144 bp insertion 6 R1,R2,R2,R3,R2,R3g,R3,R2,R2,R3,R4 n.d. gCJD n.d. [9]
144 bp insertion 6 R1,R2,R2,R3g,R3,R4 n.d. gCJD n.d. [108]
168 bp insertion 7 R1,R2,R2c,R3,R2,R3,R2,R3,R2,R3g,R3,R4 n.d. gCJD n.d. [109]
168 bp insertion 7 R2,R2,R2,R2,R3g,R2,R2 VV gCJD n.d. [38]
168 bp insertion 7 R1,R2,R2,R2,R2,R2,R3g,R2,R3g,R2a,R3,R4 MM gCJD n.d. [110]
168 bp insertion 7 R1,R2,R2,R3,R2,R2,R3g,R2,R2,R2,R3,R4 MM gCJD n.d. [111]
168 bp insertion 7 R1,R2,R2,R3,R2,R2,R3g,R2,R2,R2,R3,R4 MM GSS n.d. [112]
168 bp insertion 7 R1,R2,R2,R3,R2,R2,R2,R3g,R2,R2,R3,R4 n.d. Dementia n.d. [113]
168 bp insertion 7 R1,R2,R2,R3,R2,R3,R2,R2,R2,R2,R3,R4 n.d. Spongiform
encephalopathy
n.d. [114]
192-bp insertion 8 R1,R2,R2,R3,R2(7),R2a,R4 VV GSS Yes [115]
192 bp insertion 8 not described in detail VV GSS Yes [116]
192-bp insertion 8 R1,R2,R2,R3,R2,R2,R2,R2a,R2,R2,R2,R3,R4 MM GSS Yes [117]
192 bp insertion 8 R1,R2,R2,R3g,R2,R2,R2,R3g,R3g,R2,R2,R3,R4 n.d. HD Yes [118]
216 bp insertion 9 not described in detail MM GSS n.d. [119]
216 bp insertion 9 R1,R2,R2,R3,R2R3,R3g,R2,R2a,R2,R3,R2,R3,R4 MM GSS n.d. [120]
216 bp insertion 9 R1,R2,R2,R3,R2,R3g,R2a,R2,R2,R2,R3g,R2,R3,R4 n.d. Dementia n.d. [121]
216 bp insertion 9 R1,R2a,R2(3),R3,R2(6),R3,R4 MM Sporadic dementia n.d. [122]
288 bp insertion 12 R1,R2,R2,R3,R2,R2,R3,R2,R3g,R2,R3g,R2,R2,
R3g,R2,R3,R4
n.d. FTD n.d. [123]
Details about the coding change, number of inserts, sequence change, codon 129 genotype, kind of disease, number of cases, and corresponding
reference are indicated for each PRNP mutation. Lacking information is marked as not-described (n.d.)
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associated with axonal swelling in granule cell layer
(torpedoes) (Fig. 2c).
Spongiform changes of the neuropil may be absent or
only focally seen in the parahippocampal region (Fig. 2d).
Abnormal PrPSc deposits can be absent (Fig. 2e) or only
focally seen in areas with spongiform changes (Fig. 2f).
Biochemical typing of FFI reveals the expression of
PrPSc type 2 (MW of unglycosylated PrP = 19 kDa). The
amount of PrPSc in FFI is typically very low.
Additionally, the resistance of PrPSc to proteinase K (PK) is
decreased which makes it difficult to detect the proteinase-
resistant fragments by Western blot (Fig. 4c). Protein aggre-
gate filtration techniques may overcome these diagnostic
problems [124].
In contrast, carriers of the PRNP D178N mutation, which
exhibit PRNP codon 129V at the same allele, are classified as
fCJD cases. This patient group shows a more abundant PK-
resistant PrPSc banding pattern (Fig. 4a). The PrPSc isoform com-
position revealed an under-representation of the unglycosylated
band at 21 kDa (PrPSc type 1) and an enrichment of PrPSc in
certain brain regions, such as the parietal and frontal cortex com-
pared to the occipital cortex, striatum, and cerebellum (Fig. 4a).
PRNP Mutations Causing GSS
GSS, originally described by Gerstmann et al. [137], has
been associated with many different point mutations (e.g.,
Fig. 1 Histopathological findings in fCJD (E200K. octa-peptide repeat
insertion (OPRI)): In E200K patients, immunohistochemical detection of
PrPSc aggregates usually reveal pattern, indistinguishable from sporadic
CJD cases (a). Some E200K cases may show stripe-like prion deposits in
the molecular layer of the cerebellum (b, c). In octa-peptide repeat inser-
tion patients, immunohistochemical detection of PrPSc aggregates usually
shows a patchy or tigroid pattern (d–h). Conventional anti-prion immu-
nohistochemistry is depicted either in brown (a–c, g–i) or in red color
(e, f) for visualization, performed according the protocol from [124,
125]. In paraffin-embedded tissue (PET) blots (a, i; [126]), prion
aggregates are stained dark brown. H&E staining in g corresponds to
immunohistochemistry in h. Magnification bars are indicated
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mutations at codons 102, 105, 117, Y145 stop mutation
etc. (Table 1) or insertional mutations of octa-peptide re-
peats (Table 2). Themost common cause of GSS is a single base
exchange at codon 102 which results in an amino acid
residue change from proline to leucine (P102L). The onset
of GSS occurs at an age between 40 and 60 years and the
percentage of family history is 70 % [9]. Clinically, GSS
is associated with prominent ataxia. Dementia usually oc-
curs at the late stage of the disease over a course of 1 to
7 years [15].
A characteristic feature of GSS is the appearance of large
multicentric PrP-amyloid plaques, stained with hematoxylin-
eosin, in the molecular layer of the cerebellum (Fig. 3a, b).
Spongiform changes are fequently missing. In some GSS pa-
tients, the composite of the PrP plaques show a halo (Fig. 3a,
d), but in others not (Fig. 3b, c, e, f).
Moreover, prominent neurofibrillary, tau-positive patholo-
gy has been observed in patients exhibiting a PRNP mutation
at codon 105, 145, and 217 [42, 138, 139].
In Western blot, GSS patients and carriers of the
PRNP P102L mutation typically show an additional
proteinase K-resistant protein fragment of 7 to 10 kDa
of molecular size. A proteinase K-resistant ladder-like
PrPSc banding pattern may also occur in GSS patients
(Fig. 4d).
PRNP Mutations with an Unknown Significance
Phenotypes of different PRNPmutations may be variable. The
majority of PRNP mutations are related to a prion or a prion-
like disease. However, certainPRNPmutations have also been
described in non-prion disease patients. For example, the octa-
repeat deletion around codon 82 with a familiar history is
linked to phenotype which is similar to Alzheimer’s disease
[140]. Another report described a family with a 288 base pair
insertion consisting of 12 octa-peptide repeats which exhibit-
ed the clinical behavior changes and neuroimaging features of
atypical frontotemporal dementia (FTD) cases [123].
Moreover, a recent report has even identified a PRNP variant,
the G127V, which completely prevents prion disease as shown
in mice but not yet in humans [35].
Fig. 2 Representative neuropathological features of FFI. Severe
neuronal loss in thalamic nuclei associated with prominent
astrogliosis and microglial activation (a). Similar changes can
also be observed in the inferior olivary nucleus (b). In the
cerebellum, extensive Purkinje cell loss can be detected (c)
frequently associated with axonal swelling in the granule cell
layer (torpedoes). Spongiform changes in molecular layer are
hardly or only focally seen and may be detected in the
parahippocampal region (d). Similarly, abnormal PrP deposits
may be absent (e, thalamus) or only focally detectable in areas
with spongiform alteration such as the subiculum or cerebellar
molecular layer (f). a–d H&E staining; e, f anti-prion immunohis-
tochemistry [124, 125]
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Fig. 3 Typical neuropathological
features of GSS. a, bGSS plaques
can be observed in the molecular






multicentric plaques. In some
cases, composite plaques show a
halo (a, d), but in others not (b, c,
e, f). c, d prion PET blot; prion




PrPSc deposits in gray matter
(brown color reaction)
Fig. 4 Detection of PK-resistant PrPSc isoform profiles by Western blot in
gCJD cases. a Analysis of PrPSc isoforms in different brain regions of an
fCJD patient carrying the D178N-129 V mutation. The banding pattern of
the D178N-129 V patient revealed an under-representation of the
unglycosylated band at 21 kDa (prion type 1). b Western blot analysis
(described previously [124, 125] of PrPSc profiles from the frontal cortex
of different fCJD patients are classified according to their PrP type. E200K
129 M-, 4-OPRI 129 M-, and V210I 129 M carriers express PrPSc type 1
(unglycosylated PrP form: 21 kDa), while E200K 129 V, 4-OPRI 129 V,
and 5-OPRI 129 M carriers exhibit PrPSc type 2 (unglycosylated PrP form:
19 kDa). In c, the PrPSc profile of an FFI patient, and in d, the PrPSc profile
of a GSS patient is shown.While PrPSc in the FFI patient is less PK resistant
with a low representation of the unglycosylated PrP band, the GSSmutation
may cause the expression of a characteristic 7–10 kDa PrPSc fragment.
Abbreviations: C control, Occ C occipital cortex, Str striatum, Cereb cere-




To date, more than 50 different mutations in PRNP that may
result in diverse clinicopathological phenotypes have been doc-
umented. Some genetic cases (GSS) even show a co-pathology
of PrPSc and amyloid beta plaques or neurofibrillary tangles.
STOPmutations in the PRNP cause quite characteristic banding
patterns of PK-resistant PrPSc in brain tissue. Since several
PRNP mutations show a disease course resembling classical
sCJD and appear to occur spontaneously with no family history
and with a variable penetrance, they may remain undiscovered.
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